Ignite Creation Date:
2024-05-06 @ 8:11 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06289374
Status:
RECRUITING
Last Update Posted:
2024-03-06
First Post:
2024-02-26
Brief Title:
Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery
Sponsor:
Imperial College London
Organization:
Imperial College London
Study Overview
Official Title:
The LABS Study Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery BIORESOURCE 2 Longitudinal
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LABS
Brief Summary:
Oesophagogastric cancer cancer of the gullet and stomach is the fifth most common cancer in England and Wales with 16000 new cases diagnosed every year Survival rates are poor with only 15 surviving beyond 5 years There is also increasing research to understand the cancer biology and factors allowing cancers to progress It is likely there is a relationship between the cancer-specific microbiome cells related to inflammation which promotes cancer progression The BIORESOURCE 1 study has established a comprehensive resource of matched samples from patients with oesophageal and gastric cancer This longitudinal study aims to obtain further matched biosamples in the follow-up period after cancer surgery to find biomarkers that may predict treatment response recurrence andor long term prognosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None